NIAID
recently announced a request for applications for an Integrated
Preclinical/Clinical AIDS Vaccine program (PAR-15-330)
Purpose:
The goal of the
Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD)
Funding Opportunity Announcement (FOA) is to facilitate the translation of
sufficiently advanced, innovative and promising vaccine candidates into early
clinical testing. The IPCAVD program is designed to enable a multi-disciplinary
team of investigators to complete all steps necessary from down-selection of a
vaccine candidate through CGMP manufacture/testing/product release and into
clinical trials.
The award will provide support for:
(1) All stages of
vaccine platform research and development through facilitation of Non-Human
Primate (NHP) proof-of concept studies and down-selection of the final lead
candidate
(2) All product
development stages including processes development, CGMP manufacturing and
formulation; and
(3)
Support for all IND-enabling studies and regulatory submissions.
The IPCAVD will not
support clinical trials. However,
investigators are expected to begin clinical studies under other funding
mechanisms no later than year five of this award. Applications
consisting of preclinical research alone without a direct pathway to clinical
testing will not be supported.
Dates:
Letter of Intent Due Date: 8 February 2016
Application Due
Date: 9 March 2016
Earliest
Project Start Date: December 2016
Award Budget:
Application budgets
are not limited but need to reflect the actual needs of the proposed project.
As a guideline, the approximate range of funding
in direct costs is expected to be $1.5 to $2.5 million per year.
The
maximum project period is 5 years.
To read
the full RFA, click on the following link: http://grants.nih.gov/grants/guide/pa-files/PAR-15-330.html
If you
are interested in applying to this grant, please contact Paul
(paul.ada@mahidol.ac.th) or Glad (gladgeorge.rot@mahidol.edu) at the Office of
Research Services.
